Professor Jorge Cortes (Georgia Cancer Center, Augusta, GA, USA) summarizes three more important abstracts, the first two from the 27th Congress of the European Hematology Association (EHA) looking at combination therapies with ruxolitinib, a JAK2 inhibitor. The third abstract was presented at the 2022 American Society of Clinical Oncology (ASCO) annual meeting, looking at rusfertide treatment in phlebotomy-dependent polycythemia vera patients.
Abstract: S197: ‘NAVITOCLAX PLUS RUXOLITINIB IN JAK INHIBITOR-NAÏVE PATIENTS WITH MYELOFIBROSIS: PRELIMINARY SAFETY AND EFFICACY IN A MULTICENTER, OPEN-LABEL PHASE 2 STUDY’ (00:10-01:29)
Abstract: S198: BET INHIBITOR PELABRESIB (CPI-0610) COMBINED WITH RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS — JAK INHIBITOR-NAÏVE OR WITH SUBOPTIMAL RESPONSE TO RUXOLITINIB — PRELIMINARY DATA FROM THE MANIFEST STUDY’ (01:29-02:30)
Abstract: 7003: Rusfertide (PTG-300) treatment in phlebotomy-dependent polycythemia vera patients. (02:30-03:49)
Disclosures: Jorge Cortes is consultant for, and has received grant/research support from Novartis, Pfizer, Takeda and Sun Pharma. He is also on the Advisory Board for Novartis and Pfizer.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
